

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 341 479 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
12.10.2005 Bulletin 2005/41

(51) Int Cl.7: **A61F 2/06**

(86) International application number:
PCT/US2001/044301

(21) Application number: **01986023.8**

(87) International publication number:
WO 2002/043619 (06.06.2002 Gazette 2002/23)

(22) Date of filing: **27.11.2001**

(54) **METHOD FOR MANUFACTURING A MEDICAL DEVICE HAVING A COATED PORTION BY LASER ABLATION**

HERSTELLUNG BESCHICHTETER MEDIZINISCHER GERÄTE MITTELS LASERABLATION
PROCEDE DESTINE A FABRIQUER UN DISPOSITIF MEDICAL COMPORTANT UNE PARTIE
REJETUE AU MOYEN D'UNE ABLATION LASER

(84) Designated Contracting States:
DE FR GB IE NL

(72) Inventor: **WEBER, Jan**
Tuam (IE)

(30) Priority: **28.11.2000 US 724503**

(74) Representative: **Vossius & Partner**
Siebertstrasse 4
81675 München (DE)

(43) Date of publication of application:
10.09.2003 Bulletin 2003/37

(73) Proprietor: **Boston Scientific Scimed, Inc.**
Maple Grove, MN 55311 (US)

(56) References cited:
EP-A- 0 689 807 EP-A- 0 842 729
EP-A- 0 951 877 WO-A-00/54704
DE-A- 19 745 294 US-A- 5 356 433

EP 1 341 479 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] This invention relates generally to a method for manufacturing a medical device. More particularly, the invention is directed to a method for manufacturing a medical device having a coated portion by laser ablation.

[0002] Implantable medical devices, such as prostheses or stents, are used to reduce restenosis after balloon angioplasty or other procedures involving catheters. Usually, the suitable medical device or stent is cylindrical in shape. The walls of the cylindrical structure can be formed of metal or polymer with openings therein, e.g., a mesh. The stent is implanted into a body lumen, such as a blood vessel, where it stays permanently, to keep the vessel open and to improve blood flow to the heart muscle and relieve symptoms. Stents can also be positioned in other parts of the body, such as the kidneys or the brain. The stent procedure is fairly common, and various types of stents have been developed and actually used. However, since the bare metal surface of the stents may trigger restenosis, the stent surface should be altered to make it more biocompatible. Stents coated with polymers have been offered to reduce likelihood of restenosis caused by the metal surface of stents. Further, there are various types of polymer coats for stents which contain drugs which are delivered to an afflicted area of a body lumen. Drugs may be either bonded chemically, physically or absorbed in the polymer matrix. Also, for the purpose of obtaining drug delivery stents, the drugs may be directly coated or immobilized onto the stents, e.g. using a binding molecule between the drug molecule and the stent surface.

[0003] Previously, such coated stents have been manufactured by shaping the body of the stents first by photo-etching, laser ablation, electron beam ablation, or any other means, and then coating the stents with polymer compositions or drug compositions by dip-coating, spray-coating or any other means. However, due to the complex geometry of the stent, applying an even coating on a metal stent is very difficult. Therefore, methods for easily manufacturing a stent with uniform coating(s) are necessary.

[0004] In addition, the polymer coating, when applied by methods in the art, tends to create bridges at small gaps or corners between stent struts. Also, in the conventional methods, wherein a coating process takes place after a shaping process, it is almost impossible to selectively coat the stent. For example, it is impossible to coat one side of a stent without coating the other side or to apply different coatings to the outside and inside of a stent.

[0005] EP-A-0 689 807 discloses a biodegradable mesh-and-film stent for use in blood vessels which is formed of a sheet of a composite mesh material formed of biodegradable high-strength polymer fibers bonded together with a second biodegradable adhesive polymer, and laminated on at least one side with a thin film

of a third biodegradable polymer. The laminated bio degradable mesh-and-film material can be cut with a laser.

[0006] EP-A-0 842 729 discloses a method of forming an intravascular device, such as a stent, without creating shock or thermal stress affected areas to or in the final product, which method employs a laser capable of producing very short pulses. In order to remove a volume of material from a workpiece to create the intravascular device, laser pulses of less than 100 picoseconds in duration are directed at the area of the workpiece to be removed, there is a need for methods of making a stent, especially a coated stent, wherein the coating(s) does not form bridges at gaps or corners, and wherein selective coating of the stent can be readily achieved.

[0007] These and other objectives are accomplished by the present invention. To achieve the aforementioned objectives, a method as recited in claim 1 has been invented for manufacturing a medical device having a coated portion by laser ablation.

[0008] An embodiment of the present invention is a method for manufacturing a medical device having a coated portion which comprises obtaining a metal structure having an inner surface and an outer surface. At least a portion of the inner or outer surface is coated with a first coating material comprising a polymer. Then, the coated structure is ablated with an ultrashort-pulse laser to form at least one opening therein to form the coated portion.

[0009] In another embodiment of the present invention, the method for manufacturing a medical device having a coated portion comprises obtaining a metal plate having a first surface and a second surface. At least a portion of the first surface or second surface is coated with a first coating material comprising a polymer. The coated plate is then ablated with an ultrashort-pulse laser to form at least one opening in the coated plate. Afterward, the coated and ablated plate is formed by folding or shaping into the medical device.

[0010] Preferred embodiments of the invention are described in the following with reference to the drawings, in which:

Fig. 1A through 1D show the steps of an embodiment of the present invention.

Fig. 1A depicts a cross-sectional view of a tubular structure.

Fig. 1B depicts a cross-sectional view of the tubular structure after a coating is applied on its inner surface.

Fig. 1C depicts a cross-sectional view of the tubular structure after another coating is applied on its outer surface.

Fig. 1D depicts a cross-sectional view of a coated tube-like portion of a medical device formed by ablating the tubular structure with a laser.

Fig. 2A through 2E show steps of another embodiment of the present invention.

Fig. 2A depicts a cross-sectional view of a plate.

Fig. 2B depicts a cross-sectional view of the plate after a coating is applied on its first surface.

Fig. 2C depicts a cross-sectional view of the plate after another coating is applied on its second surface.

Fig. 2D depicts a cross-sectional view of the coated plate after laser ablation.

Fig. 2E depicts a cross-sectional view of a coated tube-like portion of a medical device made by forming the ablated plate into a desired shape.

[0011] In a method of the present invention, a structure or a plate is coated first, and then, ablated by a laser to form openings. Such ablation is conducted with an ultrashort-pulse laser. "Ultrashort-pulse lasers" refer to lasers (light amplification by stimulated emission of radiation) producing pulses with durations shorter than about 10 pico ($=10^{-11}$) second. The ultrashort-pulse laser is clearly distinguished from conventional continuous wave and long-pulse lasers (nanosecond (10^{-9} sec) laser) which have significantly longer pulses.

[0012] When a material is ablated by a conventional laser, the material is removed by thermal ablation wherein the material is locally heated to near melting point or boiling point. Thus, ablation using conventional lasers has various problems. For example, the ablation is furthermore accompanied by a heat transfer and a strong thermal shock to surrounding material which might cause serious damage, such as cracking. Also, the material once removed tends to redeposit or re-solidify on the surrounding surface. Thus, a material ablated by a conventional laser must be cleaned to remove the redeposited material surrounding the cut surface. Hence, if a material having an immobilized molecule on its surface is ablated by a conventional laser, because a clearing step is required, the immobilized molecule may be washed away at the cleaning step. Also, since process parameters for a conventional laser ablation, such as boiling point and absorption of the laser light, vary according to materials to be ablated, a layered material consisting of layers made of different materials cannot be ablated by a conventional laser.

[0013] On the other hand, ablation using an ultrashort-pulse laser is free from such problems. The ultrashort-pulse deposits its energy so quickly that it does not interact at all with the plume of vaporized material, which would distort and bend the incoming beam and produce a rough-edged cut. The plasma plume leaves the surface very rapidly, ensuring that it is well beyond the cut edges before the arrival of the next laser pulse. Since the pulse is very short, atoms in a material to be ablated are stationary in space with respect to the pulse duration. As a result, the ultrashort-pulse laser does not react differently between dielectric materials and electric materials. Thus, any material, including glasses, polymers, ceramics, silicon, and metals, can be ablated with very high precision without damage in surrounding areas by ultrashort-pulse lasers due to the absence of

heat shock waves. In addition, the surface ablated with an ultrashort-pulse laser has an excellent quality which does not need further polishing as required for a surface ablated with a conventional laser because redeposition is less or absent.

[0014] The lasers suitable for use in the method of the present invention are preferably ultrashort-pulse lasers producing pulses shorter than about 10^{-11} seconds, preferably shorter than about 10^{-12} seconds, and most preferably shorter than about 10^{-13} seconds which are referred to as femtosecond lasers.

[0015] The intensity (fluence) of the laser radiation that is required to ablate a material is dependent on the material to be ablated. Specifically each material has its own laser-induced optical breakdown (LIOB) threshold which characterizes the fluence required to ablate the material at a particular pulse width. Also the fluence of the ultrashort-pulse laser suitable for the present invention can be chosen according to the thickness of the tube wall, the thickness of the coating and each material. Furthermore, the number of pulses needed to ablate completely through a material can be calculated for a given energy or fluence.

[0016] For example, a hole without any redeposition can be drilled into a 0.7 mm-thick stainless steel plate coated with a 0.3 mm-thick poly(ethylene terephthalate) coating on its one surface, using a laser with a pulse duration of 220 femtoseconds and a fluence of 0.6 J/cm² at a wavelength of 780 nm with a repetition rate of 1 kHz, e.g., a commercial femtosecond Ti:sapphire laser and amplifier system (SPECTRA-PHYSICS, SPIT-FIRE). As another example, a hole without any redeposition can be drilled into a 0.7 mm-thick piece of tantalum with a 0.3 mm-thick poly(ethylene oxide)/poly(butylene terephthalate) copolymer coating using a laser with a pulse duration of 120 femtoseconds and a fluence of 0.5 J/cm² with the same system used above.

[0017] The laser ablation of the present invention can be conducted using any additional techniques for improved accuracy and efficiency of such ultrashort-pulse laser ablation, e.g. diffractive optical elements (DOEs) and/or polarization trepanning. See C. Momma et al., *Beam delivery of femtosecond laser radiation by diffractive optical elements*, Appl. Phys. A 67, 517-520 (1998); S. Nolte et al., *Polarization effects in ultrashort-pulse laser drilling*, Appl. Phys. A 68, 563-567 (1999).

[0018] The ultrashort-pulse lasers are known to artisans. For example, they are thoroughly disclosed by M. D. Perry et al. in *Ultrashort-Pulse Laser Machining*, Section K-ICALEO 1998, pp. 1-20.

[0019] An embodiment of the present invention is illustrated in Figures 1A-1D in which a tubular structure made of a suitable medical device material is coated with a coating material or composition. Fig. 1A depicts a cross-sectional view of a tubular structure 10 made of a suitable medical device material. The inner surface of the tubular structure 10 is coated with first coating material or composition 12 (Fig. 1B). Then, the outer sur-

face of the tubular structure 10 is also coated with second coating material or composition 14 (Fig. 1C) which can be the same as the first coating material or composition. The tubular structure 10 having an inner coating 12 and outer coating 14 is ablated by an ultrashort-pulse laser to form openings that made up a geometric pattern in the tubular structure (Fig. 1D). In this manner, a coated tube-like portion of a medical device 16 is formed. Alternatively, only one of the surfaces, e.g. inner or outer, may be coated.

[0020] Another embodiment is illustrated in Figures 2A-2E. Fig. 2A depicts a cross-sectional view of a plate 20 made of a suitable medical device material. A first surface of the plate 20 is coated with first coating material or composition 22 (Fig. 2B). Then, the second surface of the plate 20 is also coated with second coating material or composition 24, which can be the same as the first coating material or composition (Fig. 2C). The plate 20 having first coating 22 and second coating 24 is ablated by an ultrashort-pulse laser to form openings that make up a geometric pattern (Fig. 2D). The plate is then folded into a desired shape to form a coated tube-like portion of a medical device 26.

[0021] The term "structure" used in relation to a medical device means any structure which is at least a part of a medical device, such as a tubular structure. Likewise, the term "coated portion" used in relation to a medical device means any portion of a medical device which has (a) coating(s) on its surface(s). An example of such coated portion is a coated tube-like portion. Medical devices that can be fabricated by the method of the present invention include those that include a tube-like or cylindrical-like portion. The tube-like portion of the medical device need not to be completely cylindrical. For instance, the cross-section of the tube-like portion can be any shape, such as rectangle, a triangle, etc., not just a circle. Such devices include, without limitation, stents and grafts. A bifurcated stent is also included among the medical devices which can be fabricated by the method of the present invention.

[0022] Preferably, the medical device is a stent. Stents suitable for the present invention include vascular stents such as self-expanding stents and balloon expandable stents. Examples of self-expanding stents are illustrated in U.S. Patent Nos. 4,655,771 and 4,954,126 issued to Wallsten and 5,061,275 issued to Wallsten *et al.* Examples of appropriate balloon-expandable stents are shown in U.S. Patent No. 4,733,665 issued to Palmaz, U.S. Patent No. 4,800,882 issued to Gianturco and U.S. Patent No. 4,886,062 issued to Wiktor.

[0023] Appropriate materials for making the structure of the medical device are Examples for such metals include titanium, stainless steel, platinum, tantalum or gold/platinum alloy.

[0024] In the present invention, the term "coating" encompasses all ways of coating, such as using plasma, dipping, spraying, etching, covering, plating, co-extruding and all modern chemical ways of attaching bio-mol-

ecules to surfaces as well as conventional coating. The surface is coated with a material by a method known to the artisans, such as dipping into a polymer, spraying a coating composition onto the surface, or attaching biomolecules to surfaces. The surface of the structure or plate is optionally subjected to a pre-treatment, such as roughing, oxidizing or adding a primer, and then coated. Adding a primer is preferable as such pre-treatment. In another embodiment, the structure or plate can be covered with a film. Further, in another embodiment, the structure or plate can be made by co-extrusion of the medical device material and the coating material. More than one coating method can be used to make a medical device. Thickness of coatings can range from almost a single layer of molecules to about 0.1 mm. Suitable thicknesses of the coating are known in the art and can be selected by artisans.

[0025] Medical devices coating materials suitable for the present invention include any coating materials for the stent which coincide a polymer and are known to the skilled artisan. Suitable coating materials include, without limitation, polymeric materials, such as poly-L-lactic acid, polycarbonate, polyethylene terephthalate, silicones, polyurethanes, thermoplastic elastomers, ethylene vinyl acetate copolymers, polyolefin elastomers, hydrogels and EPDM rubbers. Such coatings include biologically active molecules, such as heparine or insulin molecules, directly attached to oxide molecules on the surface of the structure as explained below.

[0026] Also, the coating can be a drug-releasing coating which immediately or gradually releases a biologically active material. Coating polymer useful for drug coating includes hydrogel polymers which are often used to contain the biologically active material and are disclosed in U.S. Patent No. 5,304,121, U.S. Patent No. 5,464,650, PCT publication WO95/03083 and U.S. Patent No. 5,120,322. However, a non-hydrogel can be also used. Although polymeric molecules can be combined with biologically active molecules, biologically active materials can be directly immobilized on the surface. As disclosed in U.S. Patent No. 5,356,433 to Rowland *et al.*, polysaccharides can be immobilized to metallic surfaces by applying an organosilane coating with amine functionality and then applying a polysaccharide using carbodiimide as a coupling agent U.S. Patent No. 5,336,518 to Narayanan *et al.* also discloses that a polysaccharide can be immobilized on a surface by applying a coat of heptafluorobutylmethacrylate (HFBMA) by radiofrequency (RF) plasma deposition, creating functional groups on the surface by RF plasma with water vapor, and then applying the polysaccharide using carbodiimide. Moreover, examples of medical devices, in particular, stents coated with polymer / biologically active material coatings are described in U.S. Patent No. 5,879,697.

[0027] The term "biologically active material" encompasses therapeutic agents, such as drugs, and also genetic materials and biological materials. The genetic

materials mean DNA or RNA, including, without limitation, of DNA/RNA encoding a useful protein stated below, intended to be inserted into a human body including viral vectors and non-viral vectors. Viral vectors include adenoviruses, gutted adenoviruses, adeno-associated virus, retroviruses, alpha virus (Semliki Forest, Sindbis, etc.), lentiviruses, herpes simplex virus, ex vivo modified cells (e.g., stem cells, fibroblasts, myoblasts, satellite cells, pericytes, cardiomyocytes, skeletal myocytes, macrophage), replication competent viruses (e.g., ONYX-015), and hybrid vectors. Non-viral vectors include artificial chromosomes and mini-chromosomes, plasmid DNA vectors (e.g., pCOR), cationic polymers (e.g., polyethyleneimine (PEI)), graft copolymers (e.g., polyether-PEI and polyethylene oxide-PEI), neutral polymers, PVP, SP1017 (SUPRATEK), lipids or lipoplexes, nanoparticles and microparticles with and without targeting sequences such as the protein transduction domain (PTD). The biological materials include cells, yeasts, bacteria, proteins, peptides, cytokines and hormones. Examples for peptides and proteins include growth factors (FGF, FGF-1, FGF-2, VEGF, Endothelial Mitogenic Growth Factors, and epidermal growth factors, transforming growth factor α and β , platelet derived endothelial growth factor, platelet derived growth factor, tumor necrosis factor α , hepatocyte growth factor and insulin like growth factor), transcription factors, proteinkinases, CD inhibitors, thymidine kinase, and bone morphogenic proteins (BMP's), such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Cells can be of human origin (autologous or allogeneic) or from an animal source (xenogeneic), genetically engineered, if desired, to deliver proteins of interest at the transplant site. The delivery media can be formulated as needed to maintain cell function and viability. Cells include whole bone marrow, bone marrow derived mono-nuclear cells, progenitor cells (e.g., endothelial progenitor cells), stem cells (e.g., mesenchymal, hematopoietic, neuronal), pluripotent stem cells, fibroblasts, macrophage, and satellite cells.

[0028] Biologically active material also includes non-genetic therapeutic agents, such as:

- anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPACK (dextrophenylalanine proline arginine chloromethylketone);
 - anti-proliferative agents such as enoxaprin, angiotensin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid, amlodipine and doxazosin;
 - anti-inflammatory agents such as glucocorticoids, betamethasone, dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine;
 - antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, methotrexate, azathioprine, adriamycin and mutamycin; endostatin, angiostatin and thymidine kinase inhibitors, taxol and its analogs or derivatives;
 - anesthetic agents such as lidocaine, bupivacaine, and ropivacaine;
 - anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin (aspirin is also classified as an analgesic, antipyretic and anti-inflammatory drug), dipyridamole, protamine, hirudin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides;
 - vascular cell growth promoters such as growth factors, Vascular Endothelial Growth Factors (VEGF, all types including VEGF-2), growth factor receptors, transcriptional activators, and translational promoters;
 - vascular cell growth inhibitors such as antiproliferative agents, growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin;
 - cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms;
 - anti-oxidants, such as probucol;
 - antibiotic agents, such as penicillin, cefoxitin, oxacillin, tobramycin;
 - angiogenic substances, such as acidic and basic fibroblast growth factors, estrogen including estradiol (E2), estriol (E3) and 17-Beta Estradiol; and
 - drugs for heart failure, such as digoxin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors including captopril and enalapril.
- [0029] In the devices made by the method of the invention, both surfaces of the tube-like portion can be coated with a same material at the same time.
- [0030] Also, one surface of the structure or plate need not be coated, while the other surface has a coating. A medical device having such portion is preferable for a drug-delivery medical device for delivering a biologically active material to a blood vessel surface while minimizing the amount of biologically active material which is delivered into the blood stream. Such a medical device is also preferable when the coating is easily damaged during implantation of the medical device, e.g., because of the unfolding shear-action of the delivery balloon.
- [0031] Further in another embodiment, inner and out-

er surfaces of the portion of the medical device can be coated with different materials. For example, a stent can have a polymer coating having an anti-thrombogenic agent on the inner surface which directly contacts blood flow and a polymer coating having an anti-inflammatory agent on the outer surface which directly contacts blood vessel wall. The inner surface and the outer surface can be coated by different methods. Also, there can be more than one coating on a surface. Furthermore, an entire surface of the medical device is not necessarily coated.

[0032] In the present invention, the coated structure or plate is ablated by an ultrashort-pulse laser to form openings. The openings along with the remaining parts of the structure or plate make up the geometric pattern structure of the medical device. The structure or plate can be moved while the laser is held stationary to ablate the structure or plate into the pattern, or alternatively, the laser can be programmed to move along a predetermined pattern by a method known to artisans. A combination of both, *i.e.* moving both the laser and the structure or plate, is also possible. In the present invention, even a coated stent having a complex stent pattern can be made with high precision. A medical device having multiple coating layers and a complicated geometry pattern can also be easily manufactured by the method of the present invention without flaws such as polymer-bridges at gaps or corners. Also, the layer thickness can be easily controlled by the method of the present invention.

[0033] In the case where a plate is coated and ablated, the plate is formed into a portion of the medical device in the way known to artisans. In case the coated portion is a tube-like portion, it is formed by forming the flat plate into a tube-like shape and attaching the opposing edges of the plate together such as by fusing the two opposing sides. A method of fusing appropriate to a stent material can be chosen. Methods of fusing include fusing by heat or using adhesive.

[0034] After the ablation of the present invention, there is no need to polish the ablated medical device to avoid rough cut surfaces because of the high quality of the cut surface.

[0035] Furthermore, a plurality of medical devices can be manufactured by coating one large structure and, as ablated it as explained above, cutting the structure into individual coated portions. For example, if the coated portion is a tube-like portion, a long tubular structure is coated first, and then ablated, and then cut into individual tube-like portions of medical devices. Likewise, a large plate can be coated first, cut into a smaller plate, and then formed into an individual coated structure and ablated. Alternatively, a large coated plate can be shaped into a large coated structure, and then it is cut into individual coated structures and ablated. In this way, a plurality of medical devices can be made by using one coating step. Also, all of the medical devices will have uniform coating thicknesses.

[0036] If necessary, the thickness of the coating can

be easily measured before the ablation step. For example, it is very useful to know an amount of a biologically active material contained in a coating material. This amount can be calculated in the present invention by measuring the thickness of the coating after the coating is placed on the medical device. For example, based on the concentration of biologically active material in the coating composition and the thickness of the coating, the amount of biologically active material placed on the device can be determined.

[0037] The description contained herein is for purposes of illustration and not for purposes of limitation. Changes and modifications may be made to the embodiments of the description and still be within the scope of the invention. Furthermore, obvious changes, modifications or variations will occur to those skilled in the art.

Claims

1. A method for manufacturing a medical device having a coated portion having at least one opening therein, wherein the method comprises the steps of:

- (a) obtaining a metal structure having a first surface and a second surface;
- (b) coating at least a portion of the first or second surface with a first coating comprising a polymer; and
- (c) ablating through the coated portion of the structure with an ultrashort-pulse laser to form at least one opening therein.

2. The method of claim 1, wherein the structure is a plate and the method further comprises the step of:

- (d) forming the ablated coated portion of the plate into a tubular medical device.

3. The method of claim 1, wherein the structure is a tube-like structure.

4. The method of claim 1, wherein the structure is a stent.

5. The method of claim 1 or 2, wherein step (b) comprises only coating the first surface of the structure with the first coating material.

6. The method of claim 1 or 2, wherein step (b) comprises only coating the second surface of the structure with the first coating material.

7. The method of claim 1 or 2, wherein step (b) comprises:

- (a) coating the first surface of the structure with the first coating material and

- (b) coating the second surface of the structure with a second coating material.
8. The method of claim 7, wherein the first coating material and the second coating material are the same. 5
 9. The method of claim 7, wherein the second coating material is a polymeric coating material.
 10. The method of claim 1 or 2, wherein the first coating material is a coating composition and the surface is coated by dipping the surface into the coating composition. 10
 11. The method of claim 1 or 2, wherein the first coating material is a coating composition and the surface is coated by spray-coating the coating composition onto the surface. 15
 12. The method of claim 1 or 2, wherein the first coating material further comprises a biologically active material. 20
 13. The method of claim 1 or 2, wherein the first coating material comprises a biologically active material, and the coating step (b) is conducted by immobilizing the first coating material onto at least a portion of the first or second surface. 25
 14. The method of claim 1 or 2, wherein the coated structure is ablated to form a plurality of openings therein that define a plurality of struts. 30
 15. The method of claim 1 or 2, further comprising the step of cutting the coated structure into sections to form more than one coated portion. 35
 16. The method of claim 15, wherein the cutting step is conducted between the coating step and the ablating step. 40
 17. The method of claim 2, wherein the medical device is a stent.
 18. The method of claim 2, wherein the coated plate is cut as it is ablated. 45
 19. The method of claim 1 or 2, wherein the ablated coated portion has a first surface area and a second surface area, wherein at least a part of the first surface area is covered with a first coating for release of a first biologically active material, and wherein the second surface area is substantially free of the first biologically active material. 50
 20. The method of claim 19, wherein the medical device is a tubular medical device and the first surface area is the outer surface of the tubular medical device 55
 - and the second surface area is the inner surface of the tubular medical device.
 21. The method of claim 19, wherein at least a part of the second surface area is covered with a second coating.
 22. The method of claim 21, wherein the second coating comprises a second biologically active material.
 23. The method of claim 19, wherein the second surface area is substantially free of a coating.

Patentansprüche

1. Verfahren zur Herstellung einer medizinischen Vorrichtung mit einem beschichteten Abschnitt mit mindestens einer Öffnung darin, wobei das Verfahren die folgenden Schritte aufweist:
 - (a) Erhalten einer Metallstruktur mit einer ersten Oberfläche und einer zweiten Oberfläche;
 - (b) Beschichten mindestens eines Abschnitts der ersten oder zweiten Oberfläche mit einer ersten Beschichtung, die ein Polymer aufweist; und
 - (c) Abladieren durch den beschichteten Abschnitt der Struktur mit einem Laser mit extrem kurzen Impulsen, um mindestens eine Öffnung darin zu bilden.
2. Verfahren nach Anspruch 1, wobei die Struktur eine Platte ist und das Verfahren ferner den folgenden Schritt aufweist:
 - (d) Formen des abladierten beschichteten Abschnitts der Platte zu einer röhrenförmigen medizinischen Vorrichtung.
3. Verfahren nach Anspruch 1, wobei die Struktur eine röhrenartige Struktur ist.
4. Verfahren nach Anspruch 1, wobei die Struktur ein Stent ist.
5. Verfahren nach Anspruch 1 oder 2, wobei der Schritt (b) das ausschließliche Beschichten der ersten Oberfläche der Struktur mit dem ersten Beschichtungsmaterial aufweist.
6. Verfahren nach Anspruch 1 oder 2, wobei der Schritt (b) das ausschließliche Beschichten der zweiten Oberfläche der Struktur mit dem ersten Beschichtungsmaterial aufweist.
7. Verfahren nach Anspruch 1 oder 2, wobei der Schritt (b) aufweist:

- (a) Beschichten der ersten Oberfläche der Struktur mit dem ersten Beschichtungsmaterial und
(b) Beschichten der zweiten Oberfläche der Struktur mit einem zweiten Beschichtungsmaterial. 5
8. Verfahren nach Anspruch 7, wobei das erste Beschichtungsmaterial und das zweite Beschichtungsmaterial identisch sind. 10
9. Verfahren nach Anspruch 7, wobei das zweite Beschichtungsmaterial ein Polymerbeschichtungsmaterial ist. 15
10. Verfahren nach Anspruch 1 oder 2, wobei das erste Beschichtungsmaterial eine Beschichtungszusammensetzung ist und die Oberfläche durch Eintauchen der Oberfläche in die Beschichtungszusammensetzung beschichtet wird. 20
11. Verfahren nach Anspruch 1 oder 2, wobei das erste Beschichtungsmaterial eine Beschichtungszusammensetzung ist und die Oberfläche durch Spritzbeschichten der Oberfläche mit der Beschichtungszusammensetzung beschichtet wird. 25
12. Verfahren nach Anspruch 1 oder 2, wobei das erste Beschichtungsmaterial ferner ein biologisch aktives Material aufweist. 30
13. Verfahren nach Anspruch 1 oder 2, wobei das erste Beschichtungsmaterial ein biologisch aktives Material aufweist und der Beschichtungsschritt (b) durch Immobilisieren des ersten Beschichtungsmaterials auf mindestens einem Abschnitt der ersten oder zweiten Oberfläche durchgeführt wird. 35
14. Verfahren nach Anspruch 1 oder 2, wobei die beschichtete Struktur abladiert wird, um mehrere Öffnungen darin zu bilden, die mehrere Streben bilden. 40
15. Verfahren nach Anspruch 1 oder 2, ferner mit dem Schritt des Schneidens der beschichteten Struktur in Teilstücke, um mehr als einen beschichteten Abschnitt zu bilden. 45
16. Verfahren nach Anspruch 15, wobei der Schneidsschritt zwischen dem Beschichtungsschritt und dem Ablationsschritt durchgeführt wird. 50
17. Verfahren nach Anspruch 2, wobei die medizinische Vorrichtung ein Stent ist.
18. Verfahren nach Anspruch 2, wobei die beschichtete Platte geschnitten wird, wenn sie abladiert ist. 55
19. Verfahren nach Anspruch 1 oder 2, wobei der abladerte beschichtete Abschnitt einen ersten Oberflächenbereich und einen zweiten Oberflächenbereich hat, wobei mindestens ein Teil des ersten Oberflächenbereichs mit einer ersten Beschichtung zur Freisetzung eines ersten biologisch aktiven Materials abgedeckt und wobei der zweite Oberflächenbereich im wesentlichen frei vom ersten biologisch aktiven Material ist.
20. Verfahren nach Anspruch 19, wobei die medizinische Vorrichtung eine röhrenförmige medizinische Vorrichtung ist und der erste Oberflächenbereich die Außenfläche der röhrenförmigen medizinischen Vorrichtung und der zweite Oberflächenbereich die Innenfläche der röhrenförmigen medizinischen Vorrichtung ist.
21. Verfahren nach Anspruch 19, wobei mindestens ein Teil des zweiten Oberflächenbereichs mit einer zweiten Beschichtung abgedeckt ist.
22. Verfahren nach Anspruch 21, wobei die zweite Beschichtung ein zweites biologisch aktives Material aufweist.
23. Verfahren nach Anspruch 19, wobei der zweite Oberflächenbereich im wesentlichen frei von einer Beschichtung ist.

Revendications

1. Procédé permettant de fabriquer un dispositif médical ayant une partie enduite ayant une moins une ouverture, dans lequel le procédé comprend les étapes suivantes :
- (a) obtenir une structure métallique ayant une première surface et une deuxième surface ;
- (b) enduire au moins une partie de la première ou de la deuxième surface avec une première enduction comprenant un polymère ; et
- (c) ablater dans la partie enduite de la structure avec une impulsion laser ultracourte pour former au moins une ouverture sur celle-ci.
2. Procédé selon la revendication 1, dans lequel la structure est une plaque et le procédé comprend en outre l'étape suivante :
- (d) former la partie enduite ablatée de la plaque dans un dispositif médical tubulaire.
3. Procédé selon la revendication 1, dans lequel la structure est une structure de type tube.

4. Procédé selon la revendication 1, dans lequel la structure est un stent.
5. Procédé selon la revendication 1 ou 2, dans lequel l'étape (b) comprend uniquement l'enduction de la première surface de la structure avec le premier matériau d'enduction.
6. Procédé selon la revendication 1 ou 2, dans lequel l'étape (b) comprend uniquement l'enduction de la deuxième surface de la structure avec le premier matériau d'enduction.
7. Procédé selon la revendication 1 ou 2, dans lequel l'étape (b) comprend :
 - (a) l'enduction de la première surface de la structure avec le premier matériau d'enduction et
 - (b) l'enduction de la deuxième surface de la structure avec un deuxième matériau d'enduction.
8. Procédé selon la revendication 7, dans lequel le premier matériau d'enduction et le deuxième matériau d'enduction sont identiques.
9. Procédé selon la revendication 7, dans lequel le deuxième matériau d'enduction est un matériau d'enduction polymère.
10. Procédé selon la revendication 1 ou 2, dans lequel le premier matériau d'enduction est une composition d'enduction et la surface est enduite en immergeant la surface dans la composition d'enduction.
11. Procédé selon la revendication 1 ou 2, dans lequel le premier matériau d'enduction est une composition d'enduction et la surface est enduite en pulvérisant la composition d'enduction sur la surface.
12. Procédé selon la revendication 1 ou 2, dans lequel le premier matériau d'enduction comprend en outre une matière biologiquement active.
13. Procédé selon la revendication 1 ou 2, dans lequel le premier matériau d'enduction comprend une matière biologiquement active, et l'étape d'enduction (b) est conduite en immobilisant le premier matériau d'enduction sur au moins une partie de la première ou de la deuxième surface.
14. Procédé selon la revendication 1 ou 2, dans lequel la structure enduite est ablatée pour former une pluralité d'ouvertures sur celle-ci qui définissent une pluralité de supports.
15. Procédé selon la revendication 1 ou 2, comprenant en outre l'étape de découpage la structure enduite en sections pour former plus d'une partie enduite.
16. Procédé selon la revendication 15, dans lequel l'étape de découpe est réalisée entre l'étape d'enduction et l'étape d'ablation.
17. Procédé selon la revendication 2, dans lequel le dispositif médical est un stent.
18. Procédé selon la revendication 2, dans lequel la plaque enduite est découpée lorsqu'elle est ablatée.
19. Procédé selon la revendication 1 ou 2, dans lequel la partie enduite ablatée a une première surface et une deuxième surface, dans lequel au moins une partie de la première surface est recouverte d'une première enduction pour libérer une première matière biologiquement active, et dans lequel la deuxième surface est sensiblement dépourvue de la première matière biologiquement active.
20. Procédé selon la revendication 19, dans lequel le dispositif médical est un dispositif médical tubulaire et la première surface est la surface externe du dispositif médical tubulaire et la deuxième surface est la surface interne du dispositif médical tubulaire.
21. Procédé selon la revendication 19, dans lequel au moins une partie de la deuxième surface est recouverte d'une deuxième enduction.
22. Procédé selon la revendication 21, dans lequel la deuxième enduction comprend une deuxième matière biologiquement active.
23. Procédé selon la revendication 19, dans lequel la deuxième surface est sensiblement dépourvue d'une enduction.




Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 2D




Fig. 2E